NEWS

In preclinical studies in mice, QTX153 reduced body weight without loss of muscle mass, and the company is preparing to start its first Phase I clinical trial in 2027. ZAMUDIO (Bizkaia), 8th October 2026 – Quimatryx, the chemistry subsidiary of Oncomatryx, has developed QTX153, an oral drug candidate for the treatment of obesity that, in … Read more

The company’s scientific advisors met in Bilbao to assess the clinical progress of its lead candidate, the Quantum ADC platform and the design of bispecific ADCs, and to help define the next steps of its R&D strategy. DERIO, 6th October 2026 – Oncomatryx gathered its Scientific Advisory Board (SAB) in Derio on 30 September. The … Read more

The company, attending its first edition as a member of AseBio, also took part in a roundtable on how collaboration can shorten the path from the lab to the clinic. DERIO (Bizkaia), 2nd October 2026 – Oncomatryx has won the attendees’ vote for best pitch in the oncology session of BIOSPAIN 2026, the largest biotechnology … Read more

The company joins the sector’s leading association to share knowledge and build synergies. DERIO (Bizkaia), 25nd September 2026 – Oncomatryx has joined AseBio, the Spanish Association of Biocompanies, as a member. Founded in 1999, AseBio brings together some 370 companies and organizations from Spain’s biotechnology sector. The association has introduced the new member with an … Read more

Following the program’s bootcamp in Madrid, the company will travel to Boston from 21 to 30 October to connect with one of the world’s leading life sciences ecosystems. MADRID, 24th September 2026 – Oncomatryx has been selected to take part in Desafía Boston 2026, an acceleration and immersion program for Spanish healthcare biotech companies. The … Read more

The peer-reviewed study demonstrates how targeting the tumor microenvironment through a novel mechanism of action can trigger immune-driven antitumor effects ZAMUDIO (Bizkaia), 15th September 2026 – A study published in Science Advances, a journal of the American Association for the Advancement of Science (AAAS), describes how OMTX305, a bispecific antibody directed against the tumor microenvironment, … Read more

The biopharmaceutical company strengthens its position as a European leader in the tumor microenvironment space in San Diego, as part of the European Innovation Council delegation SAN DIEGO, 15th July 2026 – Oncomatryx Biopharma, the leading biopharmaceutical company developing antibody-drug conjugates (ADCs) targeting the tumor microenvironment, took part in the 2026 BIO International Convention as … Read more

Banco Santander and the Spanish Chamber of Commerce present the 2025 National SME of the Year Award Thursday, February 19, 2026. Oncomatryx has received the Innovation and Digitalization Award at the 9th edition of the National SME of the Year Awards, organized by Banco Santander and the Spanish Chamber of Commerce. King Felipe VI presented … Read more